首页> 美国卫生研究院文献>Disease Markers >Serum Levels of Selected Th17 and Th22 Cytokines in Psoriatic Patients
【2h】

Serum Levels of Selected Th17 and Th22 Cytokines in Psoriatic Patients

机译:银屑病患者选择的Th17和Th22细胞因子的血清水平

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction. Psoriasis is a T cell-mediated inflammatory disease in which pathogenesis T helper (Th) lymphocytes (Th1, Th17, and Th22) play an important role. The aim of the study was to assess the serum levels of some cytokines involved in the Th17 and Th22 responses in psoriatic patients. Material and Methods. The study comprised 60 psoriatic patients and 30 healthy controls. In the serum collected from psoriatic patients and healthy controls, the concentrations of IL-6, IL-12, IL-17, IL-20, IL-22, and IL-23 were examined with ELISA kits. Severity of psoriatic skin lesions was assessed by means of PASI, BSA, and PGA scores. Results. IL-6, IL-20, and IL-22 concentrations were significantly higher in psoriatic patients in comparison with the control group. The positive correlations between the concentrations of IL-22 and IL-20 and severity of psoriasis assessed with PASI and BSA scores as well as IL-17 and PASI score were found. There was also a positive correlation between IL-23 and IL-17 concentrations. Conclusions. Results of the conducted studies suggest that Th22 response may contribute to the skin and systemic inflammatory disease in psoriasis. It seems that early identification of soluble biomarkers and initiation of well-matched treatment may prevent exacerbation and progression of psoriasis.
机译:介绍。牛皮癣是一种T细胞介导的炎症性疾病,其中发病机理的T辅助(Th)淋巴细胞(Th1,Th17和Th22)起着重要作用。该研究的目的是评估银屑病患者参与Th17和Th22反应的某些细胞因子的血清水平。材料与方法。该研究包括60名银屑病患者和30名健康对照。用ELISA试剂盒检查从银屑病患者和健康对照者收集的血清中IL-6,IL-12,IL-17,IL-20,IL-22和IL-23的浓度。通过PASI,BSA和PGA评分评估牛皮癣皮肤病变的严重程度。结果。与对照组相比,银屑病患者的IL-6,IL-20和IL-22浓度明显更高。发现IL-22和IL-20的浓度与牛皮癣严重程度之间的正相关性(通过PASI和BSA评分以及IL-17和PASI评分评估)。 IL-23和IL-17浓度之间也呈正相关。结论。进行的研究结果表明,Th22反应可能导致牛皮癣的皮肤和全身性炎症性疾病。似乎早期发现可溶性生物标志物并开始进行良好匹配的治疗可预防牛皮癣的恶化和进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号